 |
|
Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial
Yoshio Hirayasu, Shin-Ichi Sato, Norifumi Shuto, Miwa Nakano, Teruhiko Higuchi
Psychiatry Investig. 2017;14(1):63-73. Published online 2016 Dec 29 DOI: https://doi.org/10.4306/pi.2017.14.1.63
|
|
A lifetime of mental health treatments for people with schizophrenia: update and narrative review
Lynn E. DeLisi
Current Opinion in Psychiatry.2024; 37(3): 140. CrossRef A clinical-stage Nrf2 activator suppresses osteoclast differentiation via the iron-ornithine axis
Yimin Dong, Honglei Kang, Renpeng Peng, Zheming Liu, Fuben Liao, Shi-an Hu, Weizhong Ding, Pengju Wang, Pengchao Yang, Meipeng Zhu, Sibo Wang, Minglong Wu, Dawei Ye, Xin Gan, Feng Li, Kehan Song
Cell Metabolism.2024; 36(8): 1679. CrossRef The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, Maurizio Fava, Mikkel Højlund, Helena C. Kraemer, Roger S. McIntyre, Daniel S. Pine, Lon S. Schneider, John M. Kane
World Psychiatry.2023; 22(1): 48. CrossRef Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
Yuanhan Bai, Guanjie Chen, Haichen Yang, Keming Gao
Journal of Affective Disorders.2020; 261: 259. CrossRef Categorizing and assessing negative symptoms
Paola Bucci, Silvana Galderisi
Current Opinion in Psychiatry.2017; 30(3): 201. CrossRef
|